# Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013

> **NIH NIH N01** · IIT RESEARCH INSTITUTE · 2023 · $659,489

## Abstract

The objectives of this Task Order are to:

1.	Determine the cross-reactivity of ATI-1013 in major organs/tissues of humans, rats, dogs, and non-human primates.
2.	Assess immunogenicity of ATI-1013 in a peripheral blood mononuclear cell assay.
3.	Conduct a dose range finding and pharmacokinetics study in rats to determine the maximum feasible/tolerated dose of ATI-1013 and single-dose ATI-1013 pharmacokinetics at that dose.
4.	Investigate the production of antidrug antibodies (ADA) to ATI-1013.
5.	Disseminate research findings.

## Key facts

- **NIH application ID:** 10932479
- **Project number:** 75N91019D00013-0-759102300001-1
- **Recipient organization:** IIT RESEARCH INSTITUTE
- **Principal Investigator:** DAVID MCCORMICK
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $659,489
- **Award type:** —
- **Project period:** 2023-09-22 → 2024-05-21

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932479

## Citation

> US National Institutes of Health, RePORTER application 10932479, Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013 (75N91019D00013-0-759102300001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10932479. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*